Summary
This clinical trial is testing whether targeted cancer medicines can help thyroid cancers become sensitive to radioactive iodine treatment again.
Some people with differentiated thyroid cancer stop responding to radioactive iodine, which is a common treatment for thyroid cancer. Researchers believe that certain targeted therapies may help these cancers take up radioactive iodine again, making the treatment effective once more.
Who can take part?
You may be eligible for this study if:
- you are aged 18 years or older
- you have differentiated thyroid cancer
- your cancer no longer responds to radioactive iodine treatment
- your cancer has a change (mutation) in either the BRAF V600E or NRAS gene
- your cancer can be measured using standard imaging scans
Study details
Participants will receive either:
- Trametinib tablets, if their cancer has a NRAS mutation, or
- Trametinib and dabrafenib tablets, if their cancer has a BRAF V600E mutation
These medicines will be taken for about 30 days.
Before starting treatment, participants will:
- Follow a low-iodine diet
- Temporarily stop their usual thyroid hormone medication and switch to an alternative thyroid hormone to help reduce symptoms
- Have specialised PET/CT scans and radioactive iodine imaging to assess how well their cancer absorbs iodine
After approximately 3 weeks of treatment, participants will have repeat scans to see whether the targeted therapy has improved iodine uptake in their cancer.
If the scans show that the cancer is absorbing enough radioactive iodine, participants will receive a standard treatment dose of radioactive iodine (iodine-131).
After treatment, participants will be monitored with regular scans, blood tests and quality of life questionnaires. Follow-up will continue for several years to assess how well the treatment works and to track long-term outcomes.